Long-term donepezil use for dementia with Lewy bodies: Results from an open-label extension of Phase III trial

Alzheimer's Research and Therapy

Volumn 7, Issue 1, 2015, Pages

  Mori, Etsuro ^a   Ikeda, Manabu ^b   Nagai, Reiko ^c   Matsuo, Kazutaka ^c   Nakagawa, Masaki ^c   Kosaka, Kenji ^d  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

^c EISAI CO LTD   (Japan)

^d YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; DONEPEZIL; PLACEBO;

ABDOMINAL DISCOMFORT; AGED; AGGRESSION; AGITATION; AKINESIA; ANXIETY DISORDER; APATHY; ARTICLE; ATRIOVENTRICULAR BLOCK; BEHAVIOR ASSESSMENT; COGNITION; COGNITIVE DEFECT; CONSCIOUSNESS DISORDER; CONSTIPATION; CONTROLLED STUDY; CONTUSION; CREATINE KINASE BLOOD LEVEL; DECREASED APPETITE; DELIRIUM; DENTAL CARIES; DEPRESSION; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIFFUSE LEWY BODY DISEASE; DIGESTIVE SYSTEM FUNCTION DISORDER; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPHAGIA; EATING DISORDER; EPIGASTRIC DISCOMFORT; FAINTNESS; FECES INCONTINENCE; FEMALE; FOOD POISONING; GASTRITIS; GASTROENTERITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; HEART PALPITATION; HEART VENTRICLE EXTRASYSTOLE; HUMAN; HYPERSALIVATION; INGUINAL HERNIA; INSOMNIA; INTESTINE OBSTRUCTION; IRRITABILITY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; MUSCLE SPASM; NAUSEA; NEUROPSYCHIATRIC INVENTORY FOR BEHAVIORAL SYMPTOM; OPEN STUDY; PARANOIA; PARKINSONISM; PERIODONTAL DISEASE; PHASE 3 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROCTALGIA; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SEXUAL AROUSAL DISORDER; SIDE EFFECT; SINUS BRADYCARDIA; SLEEP DISORDER; SOMNOLENCE; STOMACH ULCER; SUPRAVENTRICULAR PREMATURE BEAT; SYSTOLIC BLOOD PRESSURE; TOOTH PAIN; TREATMENT DURATION; TREATMENT OUTCOME; TREMOR; UNIFIED PARKINSON DISEASE RATING SCALE; UPPER ABDOMINAL PAIN; VISUAL HALLUCINATION; VOMITING; XEROSTOMIA;

EID: 84925874293     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/s13195-014-0081-2     Document Type: Article

References (33)

1. McKeith I, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-Mansfield J, et al. International Psychogeriatric Association Expert Meeting on DLB: Dementia with Lewy bodies. Lancet Neurol. 2004;3:19-28.
2. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996;47:1113-24.
3. Ballard C, O'Brien J, Morris CM, Barber R, Swann A, Neill D, et al. The progression of cognitive impairment in dementia with Lewy bodies, vascular dementia and Alzheimer's disease. Int J Geriatr Psychiatry. 2001;16:499-503.
4. Ballard C, Patel A, Oyebode F, Wilcock G. Cognitive decline in patients with Alzheimer's disease, vascular dementia and senile dementia of Lewy body type. Age Ageing. 1996;25:209-13.
5. Olichney JM, Galasko D, Salmon DP, Hofstetter CR, Hansen LA, Katzman R, et al. Cognitive decline is faster in Lewy body variant than in Alzheimer's disease. Neurology. 1998;51:351-7.
6. Walker Z, McKeith I, Rodda J, Qassem T, Tatsch K, Booij J, et al. Comparison of cognitive decline between dementia with Lewy bodies and Alzheimer's disease: a cohort study. BMJ Open. 2012;2:e000380.
7. Imamura T, Hirono N, Hashimoto M, Kazui H, Tanimukai S, Hanihara T, et al. Fall-related injuries in dementia with Lewy bodies (DLB) and Alzheimer's disease. Eur J Neurol. 2000;7:77-9.
8. Kudo Y, Imamura T, Sato A, Endo N. Risk factors for falls in community-dwelling patients with Alzheimer's disease and dementia with Lewy bodies: walking with visuocognitive impairment may cause a fall. Dement Geriatr Cogn Disord. 2009;27:139-46.
9. Hanyu H, Sato T, Hirao K, Kanetaka H, Sakurai H, Iwamoto T. Differences in clinical course between dementia with Lewy bodies and Alzheimer's disease. Eur J Neurol. 2009;16:212-7.
10. Ballard C, Walker M, O'Brien J, Rowan E, McKeith I. The characterisation and impact of 'fluctuating' cognition in dementia with Lewy bodies and Alzheimer's disease. Int J Geriatr Psychiatry. 2001;16:494-8.
11. Boström F, Jönsson L, Minthon L, Londos E. Patients with dementia with lewy bodies have more impaired quality of life than patients with Alzheimer disease. Alzheimer Dis Assoc Disord. 2007;21:150-4.
12. Lee DR, McKeith I, Mosimann U, Ghosh-Nodyal A, Thomas AJ. Examining carer stress in dementia: the role of subtype diagnosis and neuropsychiatric symptoms. Int J Geriatr Psychiatry. 2013;28:135-41.
13. McKeith IG, Rowan E, Askew K, Naidu A, Allan L, Barnett N, et al. More severe functional impairment in dementia with lewy bodies than Alzheimer disease is related to extrapyramidal motor dysfunction. Am J Geriatr Psychiatry. 2006;14:582-8.
14. Perry EK, Haroutunian V, Davis KL, Levy R, Lantos P, Eagger S, et al. Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. Neuroreport. 1994;5:747-9.
15. Perry EK, Irving D, Kerwin JM, McKeith IG, Thompson P, Collerton D, et al. Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson's and distinction from Alzheimer disease. Alzheimer Dis Assoc Disord. 1993;7:69-79.
16. Edwards K, Royall D, Hershey L, Lichter D, Hake A, Farlow M, et al. Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 24-week open-label study. Dement Geriatr Cogn Disord. 2007;23:401-5.
17. Grace J, Daniel S, Stevens T, Shankar KK, Walker Z, Byrne EJ, et al. Long-Term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial. Int Psychogeriatr. 2001;13:199-205.
18. Mori S, Mori E, Iseki E, Kosaka K. Efficacy and safety of donepezil in patients with dementia with Lewy bodies: preliminary findings from an open-label study. Psychiatry Clin Neurosci. 2006;60:190-5.
19. Rowan E, McKeith IG, Saxby BK, O'Brien JT, Burn D, Mosimann U, et al. Effects of donepezil on central processing speed and attentional measures in Parkinson's disease with dementia and dementia with Lewy bodies. Dement Geriatr Cogn Disord. 2007;23:161-7.
20. Thomas AJ, Burn DJ, Rowan EN, Littlewood E, Newby J, Cousins D, et al. A comparison of the efficacy of donepezil in Parkinson's disease with dementia and dementia with Lewy bodies. Int J Geriatr Psychiatry. 2005;20:938-44.
21. McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet. 2000;356:2031-6.
22. Mori E, Ikeda M, Kosaka K. Donepezil-DLB Study Investigators: Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. Ann Neurol. 2012;72:41-52.
23. Ikeda M, Mori E, Kosaka K, Iseki E, Hashimoto M, Matsukawa N, et al. Donepezil-DLB Study Investigators: Long-term safety and efficacy of donepezil in patients with dementia with Lewy bodies: results from a 52-week, open-label, multicenter extension study. Dement Geriatr Cogn Disord. 2013;36:229-41.
24. Ikeda M, Mori E, Matsuo K, Nakagawa M, Kosaka K. Donepezil for dementia with Lewy bodies: a randomized placebo-controlled, confirmatory phase III trial. Alzheimers Res Ther. in press.
25. Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology. 1997;48:S10-6.
26. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308-14.
27. Hashimoto M, Manabe Y, Mori E, Hirono N, Kosaka K, Ikeda M. Content validity and inter-rater reliability of the Cognitive Fluctuation Inventory. Brain Nerve [in Japanese]. 2014;66:175-83.
28. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17:427-42.
29. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state. a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-98.
30. Zarit SH, Reever KE, Bach-Peterson J. Relatives of the impaired elderly: correlates of feelings of burden. Gerontologist. 1980;20:649-55.
31. Fahn SER: UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn SMC, Calne D, Goldstein M, editors. Recent developments in Parkinson's disease, vol. 2. New York: Macmillan Healthcare Information; 1987. p. 153-63. 293-304.
32. Tohgi H, Homma A, Imai Y, Udaka F, Takeda M, Nishimura T, et al. Long-term safety and efficacy of acetylcholinesterase inhibitor E2020 in patients with Alzheimer-type dementia: 52-week open label study. Clin Eval. 2000;28:97-126.
33. Homma A, Imai Y, Tago H, Asada T, Shigeta M, Iwamoto T, et al. Long-term safety and efficacy of donepezil in patients with severe Alzheimer's disease: results from a 52-week, open-label, multicenter, extension study in Japan. Dement Geriatr Cogn Disord. 2009;27:232-9.